Brevan Howard Capital Management’s Nuvation Bio NUVB Stock Holding History

Brevan Howard Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-52,655	Closed	-$226K	–	2432
2026 Q1	$226K	Buy	+52,655	New	+$293K	﹤0.01%	1822
2025 Q4	–	Sell	-203,002	Closed	-$751K	–	2141
2025 Q3	$751K	Sell	203,002 -29,795	-13%	-$81.2K	﹤0.01%	1050
2025 Q2	$454K	Buy	232,797 +176,137	+311%	+$367K	﹤0.01%	1393
2025 Q1	$99.7K	Buy	+56,660	New	+$129K	﹤0.01%	1053
2024 Q4	–	Sell	-53,632	Closed	-$123K	–	1315
2024 Q3	$123K	Buy	+53,632	New	+$164K	﹤0.01%	1056
2024 Q1	–	Sell	-32,723	Closed	-$49.4K	–	1245
2023 Q4	$49.4K	Buy	+32,723	New	+$42.1K	﹤0.01%	995

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Brevan Howard Capital Management's NUVB Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Nuvation Bio (NUVB) in Q2 2026, closing a stake of 52,655 shares — an estimated $226K sold.

Brevan Howard Capital Management first reported a position in NUVB in Q4 2023 and held it in 6 quarters. The position peaked at $751K in Q3 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

Brevan Howard Capital Management reported no remaining Nuvation Bio position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 52,655 Nuvation Bio shares in Q2 2026, an estimated $226K.
Brevan Howard Capital Management first reported a position in Nuvation Bio in Q4 2023 and held it in 6 quarters.
Brevan Howard Capital Management's Nuvation Bio position peaked at $751K in Q3 2025.
244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.